Merck KGaA agreed to buy Silence Therapeutics for about $1.3 billion, aiming to bring the RNAi candidate divesiran into a pivotal pathway for polycythemia vera. The all-cash offer values Silence at a premium and follows Merck KGaA’s broader push to add specialized “genetic medicines” assets to its pipeline. Silence’s divesiran is a short-interfering RNA therapy built for targeted benefit in PV, where current options can control disease activity but do not change the underlying biology. Analysts highlighted the Phase 2 efficacy profile as positioning the program for a strong Phase 3 push, although the transaction still leaves execution risk tied to confirmatory trial outcomes. If the acquisition closes in 1Q 2027, Merck KGaA would expand its presence in rare and specialty diseases with a platform modality that is still finding its competitive niche versus other RNA approaches. The deal also signals continued investor appetite for differentiated dosing and delivery claims within RNA medicine.